Pular para o conteúdo principal
Ranking Invest

VERV - Verve Therapeutics, Inc.

Segmento: HealthcareVerve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Análise Ranking Invest

Valuation estimado
-$ 154.25 Mi
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 473.51 Mi

Dívida Líquida

-$ 27.92 Mi

L4T

-$ 181.01 Mi

MM4T

-487.79%

Indicadores Básicos

ROE

-38.23%

Índices de Previsibilidade

Receita Líquida

F0.54

Lucro

B0.16

Margem

D1.00

Índices de Tendência

Receita Líquida

A11.26

Lucro

F-4.57

Margem

D0.09

Índices de Endividamento

DIV/PAT

-0.06

DIV/L4T

0.15

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.